Skip to main content
. 2019 Jan 17;31(2):180–187. doi: 10.1016/j.joco.2018.12.006

Fig. 4.

Fig. 4

Indocyanine green angiography (ICGA) detection of disease recurrence during therapy tapering. A. Disease controlled under Myfortic® (1440 daily). Scars are visible as therapy had been started ∼4 years after disease onset but no active hypofluorescent dark dots (HDDs) are present. B. Thirteen months after reduction of Myfortic dosage to 720 mg, massive reappearance of HDDs, that responded to the introduction to cyclosporine (CsA) with disappearance of HDDs (C).